IMMUNABS
3.8.2022 16:02:08 CEST | Business Wire | Press release
ImmunAbs Inc. (www.immunabs.com ) announced that it has received US FDA approval for a Phase 1 clinical trial and that it is now ready to initiate a phase 1 clinical trial in the United States.
ImmunAbs is developing IM-101, a monoclonal antibody targeting complements that play essential roles in the immune system but, when out of regulation, cause various autoimmune diseases, including but not limited to paroxysmal nocturnal hemoglobinuria (PNH). The complement inhibitors drug market showed its growth potential by achieving an average annual growth rate of 20.7% and a market size of USD $ 5.1 billion in 2020 and is expected to grow to USD $19 billion by 2027.
Paroxysmal nocturnal hemoglobinuria is one example of complement-mediated autoimmune diseases where the membrane proteins protecting the red blood cells from complement activation are lost due to mutations, which results in red blood cells being destructed by the complements. Due to insufficient inhibition of complements shown by currently approved complement inhibitors, SolirisⓇ and UltomirisⓇ , patients who receive these drugs still suffer from the residual symptoms of PNH, which include anaemia, fatigue, and decreased productivity at work.
ImmunAbs’ new complement therapeutic IM-101 targets the safest and most potent component of the complement system, complement C5. IM-101 has been shown to completely inhibit complement activation, and thus is expected to alleviate the symptoms that persist with the standard of care. ImmunAbs will initiate a phase 2a clinical trial in the United States in 2024.
“This is a historical milestone for ImmunAbs.” said Dr. DongJo Kim, the company’s CEO. “We are delighted to see IM-101’s efficacy in humans which has been proven in our ex vivo study. We hope that our IM-101 will reach patients who may suffer from symptoms that persist due to insufficient complement inhibition by the current treatments.”
About ImmunAbs Inc.
ImmunAbs Inc. was established in 2017 by experts of global standard antibody therapeutics development. The vision is "Hope for Patients, Dreams for All." Currently, ImmunAbs has several antibody therapeutics in global standard development for autoimmune diseases, diabetic retinopathy, and metabolic syndrome. ImmunAbs successfully raised KRW 18.1 billion from Seed to series A funding in 2021 and got a non-clinical study national grant for developing IM-101 from Korea Drug Development Fund in November last year.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220803005380/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
C.H. Guenther Opens Centre of Excellence in Coventry, UK to Accelerate Bakery Innovation and Support Future Manufacturing Growth Across UK and Europe2.9.2026 18:00:00 CEST | Press release
C.H. Guenther & Son LLC (“C.H. Guenther” or “CHG”), a leading food manufacturer, has opened a new Centre of Excellence (the “Centre”) at its flagship Coventry bakery, creating a dedicated innovation and customer collaboration hub designed to accelerate the development of premium bakery products across the UK and Europe. The new facility has been designed to support CHG’s customers including leading global quick service restaurants, foodservice operators and retailers as they develop, test and refine new bakery products. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260902696890/en/ The purpose-built, 172-square-metre Centre of Excellence brings together a commercial-scale bakery, customer demonstration kitchen, sensory evaluation facilities, innovation suite and dedicated collaboration spaces in one specialized location. Designed to support and accelerate product development from concept through to commercial manufacturing,
Record Asset Management Enters New Phase of Growth2.9.2026 17:35:00 CEST | Press release
Record Asset Management GmbH (“RAM”), a subsidiary of London-listed Record plc (“Record” or the “Group”), is pleased to announce that it is now operating cashflow positive, thereby marking a transition from its investment phase into a growth business within the Group, and a significant milestone towards sustainable profitability. RAM is the European asset management arm of Record, the London-listed specialist investment group managing USD 122 billion of assets on behalf of institutional clients worldwide. Record's client base comprises pension funds, foundations, sovereign institutions and other asset managers, with whom the Group has built long-standing relationships through its focus on bespoke investment and risk management solutions. RAM was established as a sister company to Record’s core currency business and obtained its BaFin license in 2022. RAM has grown rapidly in the last two years and has developed into a diversified private markets platform with dedicated infrastructure e
Doha Debates Holds Toronto Town Hall on Football, Money and Fandom2.9.2026 17:10:00 CEST | Press release
A sports journalist, a historian and a filmmaker join students from Qatar, Canada and Mexico to debate the impact of wealthy club backing on football and its fans Football fans embody club loyalty that no boardroom can manufacture. But as global capital reshapes the world’s most-watched sport, who it belongs to is increasingly contested. This question is at the heart of Qatar Foundation’s latest Doha Debates town hall, “Football fandom: Community or commodity?”, now available on Doha Debates and Al Jazeera Digital platforms. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260902833406/en/ Doha Debates Town Hall “Football fandom: Community or commodity?” stage at the Terminal Theatre in Toronto, Canada. (Photo: AETOSWire) The episode was filmed at The Terminal Theatre in Toronto in partnership with the Qatar, Canada and Mexico 2026 Year of Culture, a national initiative that builds lasting relationships between countries by cr
Honoring the World’s Most Exceptional Tourism Destinations: Nominations Now Open for the Second TOURISE Awards2.9.2026 15:55:00 CEST | Press release
The TOURISE Awards showcase the globe's most influential destinations, highlighting the richness of culture, the power of human connection, and groundbreaking advancements in travel. Six categories are open for nominations, including a new award for Best Wellness Destination, plus a flagship Best Overall Destination award selected by the jury. Winners will be honored at the TOURISE Awards ceremony, held in conjunction with the TOURISE Summit in Riyadh, March 23-25, 2027. The second cycle of the TOURISE Awards officially launched today as a continuing global benchmark celebrating premier tourism destinations. The TOURISE Awards set a new global benchmark in 2025, celebrating destinations that deliver distinctive, purpose-driven travel experiences. In 2027, TOURISE will celebrate the destinations shaping tomorrow’s tourism; that deliver value across the entire journey, align with traveler purpose, and set new global standards for how the world travels, connects, and grows. Nominations ar
ABB Extends Engagement with Wipro to Deliver and Enhance Global Digital Workplace Services2.9.2026 15:30:00 CEST | Press release
Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading AI-powered technology services and consulting company, has renewed its long-standing Digital Workplace Services contract with ABB, a global technology leader in electrification and automation. Building on an established relationship spanning multiple years, Wipro will continue delivering end-to-end AI-enabled Digital Workplace Services for ABB's global operations while further enhancing employee experience through advanced automation, AI-powered service capabilities, and workplace modernization initiatives. Powered by Wipro Intelligence™, the unified suite of AI platforms, solutions and transformative offerings, this engagement will modernize ABB’s digital workplace with AI-led, experience-centric capabilities delivered through Wipro’s AI Live Workspace™ and Digital Workplace Services offerings and operationalized through WINGS, Wipro’s AI-powered delivery platform for operations. Through SmartOps, Wipro’s AIOps capability,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom